# A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

> **NCT03403712** · PHASE3 · COMPLETED · sponsor: **Helsinn Healthcare SA** · enrollment: 404 (actual)

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** fosnetupitant/ palonosetron
- **DRUG:** netupitant/palonosetron
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT03403712
- **Lead sponsor:** Helsinn Healthcare SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-16
- **Primary completion:** 2018-09-19
- **Final completion:** 2018-09-19
- **Target enrollment:** 404 (ACTUAL)
- **Last updated:** 2020-06-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03403712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03403712, "A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03403712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*